Miyajima A - Search Results

1

Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer.

Shirotake S, Miyajima A, Kosaka T, Tanaka N, Maeda T, Kikuchi E, Oya M. Shirotake S, et al. Among authors: miyajima a. Urology. 2011 Apr;77(4):1009.e19-25. doi: 10.1016/j.urology.2010.11.002. Epub 2011 Feb 5. Urology. 2011. PMID: 21296393

2

Captopril restores transforming growth factor-beta type II receptor and sensitivity to transforming growth factor-beta in murine renal cell cancer cells.

Miyajima A, Asano T, Hayakawa M. Miyajima A, et al. J Urol. 2001 Feb;165(2):616-20. doi: 10.1097/00005392-200102000-00083. J Urol. 2001. PMID: 11176447

3

Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis.

Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, Hayakawa M. Miyajima A, et al. Cancer Res. 2002 Aug 1;62(15):4176-9. Cancer Res. 2002. PMID: 12154013

4

Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction.

Miyajima A, Kosaka T, Seta K, Asano T, Umezawa K, Hayakawa M. Miyajima A, et al. J Urol. 2003 Apr;169(4):1559-63. doi: 10.1097/01.ju.0000045686.21766.c1. J Urol. 2003. PMID: 12629415

5

Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma.

Miyajima A, Asano T, Seta K, Asano T, Kakoi N, Hayakawa M. Miyajima A, et al. Urology. 2003 May;61(5):1072-7. doi: 10.1016/s0090-4295(02)02553-0. Urology. 2003. PMID: 12736050

6

Differential expression of activator protein-2 isoforms in renal cell carcinoma.

Oya M, Mikami S, Mizuno R, Miyajima A, Horiguchi Y, Nakashima J, Marumo K, Mukai M, Murai M. Oya M, et al. Among authors: miyajima a. Urology. 2004 Jul;64(1):162-7. doi: 10.1016/j.urology.2004.02.022. Urology. 2004. PMID: 15245963

7

Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction.

Mizuguchi Y, Miyajima A, Kosaka T, Asano T, Asano T, Hayakawa M. Mizuguchi Y, et al. Among authors: miyajima a. J Urol. 2004 Dec;172(6 Pt 1):2456-9. doi: 10.1097/01.ju.0000138473.38447.f0. J Urol. 2004. PMID: 15538290

8

Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.

Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, Murai M. Kuroda K, et al. Among authors: miyajima a. Clin Cancer Res. 2005 Aug 1;11(15):5590-4. doi: 10.1158/1078-0432.CCR-04-2561. Clin Cancer Res. 2005. PMID: 16061877

9

Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.

Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M. Kosugi M, et al. Among authors: miyajima a. Clin Cancer Res. 2006 May 1;12(9):2888-93. doi: 10.1158/1078-0432.CCR-05-2213. Clin Cancer Res. 2006. PMID: 16675585

10

Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.

Kikuchi E, Nakashima J, Ishibashi M, Ohigashi T, Oya M, Nakagawa K, Miyajima A, Murai M. Kikuchi E, et al. Among authors: miyajima a. Urology. 2006 Aug;68(2):371-5. doi: 10.1016/j.urology.2006.02.031. Urology. 2006. PMID: 16904455

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

724 results

Search Page

Filters